Liquidia Corp
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Arquitos Capital reported a -51.9% net return in Q3 2026, with YTD return at -26.5%. The decline was driven by a district court ruling against Liquidia, causing its shares to drop from $71 to $30. Arquitos' holdings in Liquidia call options expired out of the money, but the fund plans to hold them.
Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.
Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning LQDA (Liquidia Corp). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent LQDA coverage spans financial news and market movers.
In the last 30 days, LQDA insiders filed 10 SEC Form 4 transactions — no purchases and 10 sales ($9.3M). The most active reporter was Khindri Sanjeev, Chief Development Officer, with 1 filing. 90% of those filings were made under pre-arranged Rule 10b5-1 plans.
Arquitos Capital reported a -51.9% net return in Q3 2026, with YTD return at -26.5%. The decline was driven by a district court ruling against Liquidia, causing its shares to drop from $71 to $30. Arquitos' holdings in Liquidia call options expired out of the money, but the fund plans to hold them.
Upgrades suggest near-term upside as analysts raise expectations.
Settlement removes ongoing litigation over YUTREPIA’s PH-ILD-related patent claims, but Liquidia takes a large cash hit and stops PH-ILD promotion.
Analyst upgrade and higher target may boost sentiment.
Settlement removes litigation cloud, likely supporting a short-term bounce.
AlphAI scores every news story that mentions LQDA with an AI model for sentiment and relevance, and aggregates insider trades from Liquidia Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Arquitos Capital reported a -51.9% net return in Q3 2026, with YTD return at -26.5%. The decline was driven by a district court ruling against Liquidia, causing its shares to drop from $71 to $30. Arquitos' holdings in Liquidia call options expired out of the money, but the fund plans to hold them.
2 min readLiquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.
1 min readLiquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.
7 min readAnalysts from Piper Sandler and other firms maintained Buy ratings on Tectonic Therapeutic (TECX), Boston Scientific (BSX), and Liquidia Technologies (LQDA). Price targets set at $76 for TECX, $60 for BSX, and $58 for LQDA. Current share prices and analyst consensus also provided.
2 min readLiquidia (LQDA) stock fell 59% in a month after a patent ruling, then settled litigation, keeping its drug available. It has a history of sharp declines but full recoveries. LQDA reported strong sales and profit margins, with rising costs expected. Management forecasts revenue growth but uncertain patient start acceleration.
2 min readLiquidia Corp (LQDA) was upgraded to Outperform by LifeSci Capital, with a price target of $59.00. The stock is currently trading at $33.94, and GuruFocus estimates it is 88.1% undervalued with a GF Value of $285.95. LQDA has a GF Score of 69, indicating fair performance with strengths in growth but challenges in profitability and valuation. Insider activity shows significant selling.
2 min readLiquidia Corporation's average stock price target increased from $52.14 to $52.71, with a range of $33 to $70. This implies 97% upside from the Oct. 13 closing price. The consensus rating remains 'Buy' among 9 analysts, with 5 Buys and 4 Holds.
1 min readLiquidia (LQDA) +25% after settling lawsuits with United Therapeutics (UTHR). Greenland Energy (GLND) +51% on Trump's Greenland resource claims. CoreWeave (CRWV) -14% on debt concerns. Bank of America (BAC) Q3 net income $6.9B. BlackRock (BLK) Q3 EPS $15.93. Morgan Stanley (MS) Q3 revenue $20.3B. ASML (ASML) Q3 sales €11.7B, warns of future demand.
3 min readUS futures rise ahead of CPI data, with small caps leading. Traders await inflation figures, bank earnings, and Anthropic's pre-IPO investor day. Oil prices increase due to Middle East tensions. Alphabet leads 'Magnificent 7' higher, while Bank of America falls on regulatory fines and trading misses. BlackRock jumps after strong quarterly inflows. CPI consensus expects 0.6% M/M and 3.6% Y/Y headline inflation.
3 min readWall Street analysts made several calls: Mizuho upgraded Albemarle (ALB) citing battery storage demand, Goldman upgraded Trane (TT) with a $565 target, Morgan Stanley reiterated SpaceX (SPCX) overweight, Barclays downgraded Dell (DELL), Jefferies upgraded Brinker (EAT), Barclays initiated Alcoa (AA) and Kaiser (KALU) as overweight, JPMorgan initiated Kirby (KEX) and Arcus (RCUS) as overweight, and reiterated Apple (AAPL) overweight.
4 min read
